Journals / Turkish Journal of Gastroenterology / 2019 / Cilt: 30 - Sayı: 1

Low molecular weight heparin treatment of acute moderate and severe pancreatitis: A randomized, controlled, open-label study

Pages
81–87
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Mortality was not significantly different between the groups (p=0.056).Conclusion: Low molecular weight heparin treatment is safe and provides better prognosis in MSAP.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/Aims: Acute pancreatitis (AP) runs a moderately severe and severe course in 20%-30% of cases.
📊
Key Findings & Data:The purpose of the present study was to determine the effect of low molecular weight heparin (LMWH) for the prevention of pancreatic necrosis (PN) in moderately severe and severe AP (MSAP).Materials and Methods: A total of 100 patients with MSAP were randomized to receive either standard care (SC) or SC plus LMWH.LMWH was administered at 1 mg/kg via subcutaneous injection twice a day between days 1 and 7.
💡
Conclusion & Impact:Mortality was not significantly different between the groups (p=0.056).Conclusion: Low molecular weight heparin treatment is safe and provides better prognosis in MSAP.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Background/Aims: Acute pancreatitis (AP) runs a moderately severe and severe course in 20%-30% of cases. The purpose of the present study was to determine the effect of low molecular weight heparin (LMWH) for the prevention of pancreatic necrosis (PN) in moderately severe and severe AP (MSAP).Materials and Methods: A total of 100 patients with MSAP were randomized to receive either standard care (SC) or SC plus LMWH.LMWH was administered at 1 mg/kg via subcutaneous injection twice a day between days 1 and 7. The revised Atlanta criteria were usedin the diagnosis of MSAP. Patients with a Harmless AP Score of ≥1 and a Balthazar computed tomography (CT) score of D and E wereincluded in the study.Results: The mean age±SD of the patients (46 male and 54 female) was 52±19 years (range, 17-100). There were 50 patients in eachgroup. On admission, clinical and laboratory parameters and Balthazar CT scores were similar between the groups. Initially, PN waspresent in one patient in the LMWH group and two in the SC group. Over the course, PN developed in 3 (6.1%) patients in the LMWHgroup and 11 (22.9%) in the SC group (p<0.05). Local and systemic complications were significantly lower in the LMWH group (p<0.05).No hemorrhagic complication occurred. Mortality was not significantly different between the groups (p=0.056).Conclusion: Low molecular weight heparin treatment is safe and provides better prognosis in MSAP.

🔖

Cite This Article

TOZLU, M., KAYAR, Y., İNCE, A. T., BAYSAL, B., ŞENTÜRK, H. (2019). Low molecular weight heparin treatment of acute moderate and severe pancreatitis: A randomized, controlled, open-label study. Turkish Journal of Gastroenterology, Cilt: 30 - Sayı: 1, 81–87. https://ajindex.com/articles/408805

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Dobosz M, Mionskowska L, Hac S, Dobrowolski S, Dymecki D, Wajda Z. Heparin improves organ microcirculatory disturbances in caerulein-induced acute pancreatitis in rats. World J Gastroenterol 2004; 10: 2553-6. [CrossRef] Kylanpaa ML, Repo H, Puolakkainen PA. Inflammation and immunosuppression in severe acute pancreatitis. World J Gastroenterol 2010; 16: 2867-72. [CrossRef] Gross V, Leser HG, Heinisch A, Scholmerich J. Inflammatory mediators and cytokines--new aspects of the pathophysiology and assessment of severity of acute pancreatitis? Hepatogastroenterology 1993; 40: 522-30. Balthazar EJ. Acute pancreatitis: assessment of severity with clinical and CT evaluation. Radiology 2002; 223: 603-13. [CrossRef] Qiu F, Lu XS, Huang YK. Effect of low molecular weight heparin on pancreatic micro-circulation in severe acute pancreatitis in a rodent model. Chin Med J (Engl) 2007; 120:2260-3.
  2. Hajjar NA, Iancu C, Bodea R. Modern therapeutic approach of acute severe forms of pancratitis. A review of the literature and experience of Surgical Department No III Cluj. Chirurgia (Bucur) 2012; 107: 605-10.
  3. McKay CJ, Evans S, Sinclair M, Carter CR, Imrie CW. High early mortality rate from acute pancreatitis in Scotland, 1984-95. Br J Surg 1999; 86: 1302-5. [CrossRef] Floyd A, Pedersen L, Nielsen GL, Thorladcius-Ussing O, Sorensen HT. Secular trends in incidence and 30-day case fatality of acute pancreatitis in North Jutland County, Denmark: a register-based study from 1981-2000. Scand J Gastroenterol 2002; 37: 1461-5. [CrossRef] Salas A, Sans M, Soriano A, Reverter JC, Anderson DC, Pique JM, et al. Heparin attenuates TNF-alpha induced inflammatory response through a CD11b dependent mechanism. Gut. 2000; 47: 88-96. [CrossRef] Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest 1998; 101: 877-89. [CrossRef] Evangelista V, Piccardoni P, Maugeri N, De Gaetano G, Cerletti C. Inhibition by heparin of platelet activation induced by neutrophil-derived cathepsin G. Eur J Pharmacol 1992; 216: 401-5. [CrossRef] Qiu F, Lu XS, Huang YK. Protective effect of low-molecular-weight heparin on pancreatic encephalopathy in se vere acute pancreatic rats. Inflamm Res 2012; 61: 1203-9. [CrossRef] Lu XS, Qiu F, Li JQ, et al. Low molecular weight heparin in the treatment of severe acute pancrea